Company intelligence / Profile preview
Micron Biomedical
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 2
Overview
Micron Biomedical’s dissolvable microneedle patch technology has demonstrated at least equivalent efficacy to traditional injections in adults and children as young as nine months old. The company recently published positive Phase 1/2 data for needle-free vaccines in children and has advanced to the world’s first Phase 2 trial of this technology in infants. The platform enables painless self-administration without needles, reduces cold chain requirements, medical waste, and can be administered by non-medical personnel—addressing key barriers to global immunization access.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Dissolvable microarray (microneedle) patches for drug and vaccine delivery
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Micron Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Micron Biomedical.